Stanolone

Stanolone

SCHEMBL3486722

C[C@]12CCC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(O)CC[C@@H]12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SHBG P04278 6/20 1.00
GPBAR1 Q8TDU6 4/20 1.00
CYP19A1 P11511 2/20 1.00
NR3C1 P04150 1/20 1.00
PGR P06401 1/20 1.00
SERPINA6 P08185 1/20 1.00
NR3C2 P08235 1/20 1.00
CYP3A4 P08684 1/20 1.00
AR P10275 1/20 1.00
HSD17B10 Q99714 1/20 1.00
MGAM O43451 1/20 1.00
AKR1B10 O60218 3/20 0.70
AKR1B1 P15121 3/20 0.70
PDK1 Q15118 2/20 0.68
PDK2 Q15119 2/20 0.68
PDK3 Q15120 2/20 0.68
PDK4 Q16654 2/20 0.68
POLB P06746 1/20 0.66
MAPK1 P28482 1/20 0.66
OR51E2 Q9H255 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Stanolone SCHEMBL619535 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR
Stanolone SCHEMBL1502216 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR
Stanolone SCHEMBL15963544 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR
Stanolone SCHEMBL24684703 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR
Stanolone SCHEMBL1570704 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR
Stanolone SCHEMBL24410503 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR
Stanolone SCHEMBL9340073 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR
Stanolone SCHEMBL333299 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR
Stanolone SCHEMBL21442439 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR
Stanolone SCHEMBL27379 1.00 SHBG (1.00) SHBGGPBAR1CYP19A1NR3C1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3458071-A1 DIHYDROTESTOSTERONE AND DIHYDROTESTOSTERONE DERIVATIVES AND PROMOTERS IN THE TREATMENT OF CANCER Tyme, Inc. (US) 2019-03-27 EP disclosed
WO-2017201217-A1 DIHYDROTESTOSTERONE AND DIHYDROTESTOSTERONE DERIVATIVES AND PROMOTERS IN THE TREATMENT OF CANCER TYME, INC. (US) 2017-11-23 WO disclosed
US-20100041631-A1 METHODS AND AGENTS FOR TREATING TUBERCULOSIS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2010-02-18 US disclosed
EP-1474127-B1 BIPHENYL DERIVATIVES AND THEIR USE AS ANTIANDROGENIC AGENTS ENDORECH INC (CA) 2006-11-15 EP disclosed
US-20060025393-A1 Steroid derivatives NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-02-02 US disclosed
US-6933321-B2 For therapy of androgen-dependent diseases such as prostate cancer, benign prostatic hyperplasia, precicious puberty, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and premature male baldness ENDORECHERCHE, INC. (CA) 2005-08-23 US disclosed
EP-1474127-A1 BIPHENYL DERIVATIVES AND THEIR USE AS ANTIANDROGENIC AGENTS Endorecherche, Inc. (CA) 2004-11-10 EP disclosed
US-20040152681-A1 Steroid derivatives ARCH DEVELOPMENT CORPORATION, AN ILLINOIS CORPORATION 2004-08-05 US disclosed
US-20040006134-A1 Antiandrogenic biphenyls ENDORECHERCHE, INC. 2004-01-08 US disclosed
US-6645955-B1 Nuclear liver X receptor (LXR) and ubiquitous receptor (UR) disorders; cancer, rheumatic arthritis, diabetes, Alzheimer*s disease ARCH DEVELOPMENT CORPORATION 2003-11-11 US disclosed
WO-2003068217-A1 BIPHENIL DERIVATIVES AND THEIR USE AS ANTIANDROGENIC AGENTS ENDORECHERCHE, INC. (CA) 2003-08-21 WO disclosed
EP-1189922-A4 STEROID DERIVATIVES ARCH DEV CORP (US) 2002-08-14 EP disclosed
EP-1189922-A1 STEROID DERIVATIVES Arch Development Corporation (US) 2002-03-27 EP disclosed
WO-2000066611-A1 STEROID DERIVATIVES ARCH DEVELOPMENT CORPORATION (US) 2000-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025393-A1 Steroid derivatives NR5A1, NR3C2, NR3C1 SHBG 21/4885GPBAR1 107/4885CYP19A1 26/4885
US-20040006134-A1 Antiandrogenic biphenyls SHBG, AR, CYP19A1 SHBG 1/4885GPBAR1 144/4885CYP19A1 3/4885
US-20040152681-A1 Steroid derivatives NR1H3, NR1H2, NR1H4 SHBG 72/4885GPBAR1 21/4885CYP19A1 97/4885
US-20100041631-A1 METHODS AND AGENTS FOR TREATING TUBERCULOSIS TKT, FNTB, ACAT1 SHBG 705/4885GPBAR1 3126/4885CYP19A1 3701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.